Physician profile
Robert Pozzi
NPI 1518948900
$14,571.53
in general payments reported to CMS, 2019-2025
58 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $1,625 · 2021: $2,588 · 2022: $2,628 · 2023: $2,154 · 2024: $1,995 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,639 · Entertainment: $14.96 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,638.69 |
| Entertainment | $14.96 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,488.32 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $1,404.14 | 2019-2025 | |
| Novo Nordisk INC | $1,346.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,276.98 | 2021-2025 | |
| Lilly USA, LLC | $1,032.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $906.03 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $673.21 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $670.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $581.13 | 2019-2023 | Myrbetriq, Veozah |
| Amgen INC. | $399.47 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.56 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $307.02 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $245.31 | 2020-2025 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $242.59 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $219.65 | 2019-2024 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.